Sino Biopharmaceutical Limited
1177
Rang in Aktien
#1753
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Aktienkurs
$0.69080164
Marktkapitalisierung
$12.30B
Veränderung (1 Tag)
2.86%
Veränderung (1 Jahr)
-27.78%
Land
HK
Handel Sino Biopharmaceutical Limited (1177)
Kategorie
Healthcare
Gewinn für Sino Biopharmaceutical Limited (1177)
Gewinn im Jun 2026 TTM: $1.21B
Laut den aktuellen Finanzberichten von Sino Biopharmaceutical Limited betragen die aktuellen Gewinne des Unternehmens $1.21B. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $764.26M, eine Steigerung gegenüber dem Gewinn im Jahr 2022, der $756.01M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Sino Biopharmaceutical Limited von 2000 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $1.21B | 66.67% |
| 2024 | $723.03M | -5.40% |
| 2023 | $764.26M | 1.09% |
| 2022 | $756.01M | -74.13% |
| 2021 | $2.92B | 280.79% |
| 2020 | $767.38M | -4.30% |
| 2019 | $801.89M | -51.74% |
| 2018 | $1.66B | 157.64% |
| 2017 | $644.90M | 33.59% |
| 2016 | $482.76M | 8.71% |
| 2015 | $444.09M | 22.80% |
| 2014 | $361.64M | 31.39% |
| 2013 | $275.23M | 19.15% |
| 2012 | $231.00M | 80.70% |
| 2011 | $127.84M | -8.96% |
| 2010 | $140.42M | 36.19% |
| 2009 | $103.10M | 33.11% |
| 2008 | $77.46M | 76.36% |
| 2007 | $43.92M | 66.73% |
| 2006 | $26.34M | 81.55% |
| 2005 | $14.51M | -64.22% |
| 2004 | $40.55M | 81.70% |
| 2003 | $22.32M | 28.38% |
| 2002 | $17.38M | 15.22% |
| 2001 | $15.09M | 37.33% |
| 2000 | $10.99M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $1.35B | 12.01% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -97.81% |
US
|
